Dtsch Arztebl Int. 2008 Oct;105(43):733-40. doi: 10.3238/arztebl.2008.0733. Epub 2008 Oct 24.
The term cancer of unknown primary site (CUP) syndrome is used to describe malignancies in which a complete diagnostic work-up detects metastases in the absence of an identifiable primary tumor.
Based on a selective literature review, national and international guidelines, and the experience of the "Arbeitskreis CUP-Syndrom der Arbeitsgemeinschaft Internistische Onkologie der Deutschen Krebsgesellschaft" (CUP Syndrome Committee of the Medical Oncology Joint Working Group of the German Cancer Society), developments in the diagnosis and treatment of CUP syndrome are reported.
Most patients diagnosed with CUP have an unfavorable prognosis, with a life expectancy of less than 12 months. Nevertheless, it is important to identify subsets of patients in whom specific treatment offers the chance of long-term survival or even full recovery.
Only rigorous further development of diagnostic tools and treatment protocols will enable an improvement of the poor prognosis of patients with CUP syndrome. Specific molecular treatment strategies have shown promising results.
不明原发灶肿瘤(CUP)综合征是指经过全面诊断仍未能确定肿瘤原发灶的恶性肿瘤。
基于选择性文献回顾、国家和国际指南以及“德国癌症协会内科肿瘤学联合工作组不明原发灶肿瘤综合征工作组”的经验,本文报告了 CUP 综合征的诊断和治疗进展。
大多数被诊断为 CUP 的患者预后不良,预期寿命不到 12 个月。然而,重要的是要识别出特定治疗有机会带来长期生存甚至完全康复的患者亚群。
只有严格进一步开发诊断工具和治疗方案,才能改善 CUP 综合征患者的不良预后。特定的分子治疗策略已经显示出有希望的结果。